Inability of the activated partial thromboplastin time to predict heparin levels: Time to reassess guidelines for heparin assays

Archives of Internal Medicine

Volumn 157, Issue 21, 1997, Pages 2475-2479

  Baker, Brian A ^a   Adelman, Michael D ^a   Smith, Patricia A ^b   Osborn, Janet C ^b  

^a Saint Vincent Health Center   (United States)

^b Clinical Pathology Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN;

ARTICLE; BLEEDING; BLOOD LEVEL; CORONARY ARTERY DISEASE; DRUG EFFICACY; HEPARINIZATION; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RECURRENT DISEASE;

EID: 0030679685     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.21.2475     Document Type: Article

References (18)

1. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the Initial treatment of proximal-vein thrombosis. N Engl J Med. 1988;315:1109-1114.
2. Chiu HM, Hirsh J, Yung WL, Regoeczi E, Gent M. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood. 1977;49:171-184.
3. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the Initial treatment of proximal venous thrombosis. N Engl J Med. 1990;322:1260-1264.
4. Turpie AG, Robinson JG, Doyle DJ, et al. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med. 1989; 320:352-357.
5. Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest. 1995;108(suppl):335S-351S.
6. Mesters RM, Mikoteit T, Schiller M, Krings W, Ostermann H, Kienast J. Markers of coagulation activation for evaluation of the antithrombotic efficacy of heparin: a prospective study in acute deep venous thrombosis. Blood Coagul Fibrinolysis. 1995;6:665-671.
7. Stevenson KJ, Easton AC, Curry A, Thomson JM, Poller L. The reliability of activated partial thromboplastin time methods and the relationship to lipid composition and ultrastructure. Thromb Haemost. 1986;55:250-258.
8. D'Angelo A, Seveso MP, D'Angelo SV, Gilardoni F, Dettori AG, Bonini P. Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT): implications in heparin monitoring by APTT. Am J Clin Pathol. 1990;94:297-306.
9. Shojania AM, Tetreault J, Turnbull G. The variations between heparin sensitivity of different lots of activated partial thromboplastin time reagent produced by the same manufacturer. Am J Clin Pathol. 1988;89:19-23.
10. Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med. 1993;119:104-109.
11. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacoklnetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1995;108(suppl):258S-275S.
12. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism: statement for healthcare professionals. From the Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation. 1996;93:2212-2245.
13. Levine MM, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med. 1994;154:49-56.
14. Teien AN, Lie M. Evaluation of an amidolytic heparin assay method: Increased sensitivity by adding purified antithrombin III. Thromb Res. 1977;10:399-410.
15. Chow GC, Tests of equality between sets of coefficients in two linear regressions. Econometrica. 1960;28:591-605.
16. Anand S, Ginsberg JS, Kearon C, Gent M, Hirsh J. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Arch Intern Med. 1996;156:1677-1681.
17. Holm HA, Finnanger B, Hartmann A, et al. Heparin treatment of deep venous thrombosis in 280 patients: symptoms related to dosage. Acta Med Scand. 1984;215:47-53.
18. Hirsh J, Van Aken WG, Gallus AS, Dollery CT, Cade JF, Yung WL. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation. 1976;53:691-695.